Total trials
321
Active
88
Phase 3
40
Total enrollment
69,923
Pipeline matrix
Showing 40 of 62 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Tamsulosin | — | — | — | — | 3 | ||
| Tadalafil | — | — | — | — | 3 | ||
| L-Citrulline | — | — | — | — | 2 | ||
| Tadalafil Placebo | — | — | — | — | — | 2 | |
| silodosin 8 mg | — | — | — | — | 2 | ||
| Clindamycin vaginal cream | — | — | — | — | — | 1 | |
| Vaginal preparation with povidone- iodide solution 10 % | — | — | — | — | — | 1 | |
| Tadalafil 5mg | — | — | — | — | — | 1 | |
| estradiol valerate 2 mg | — | — | — | — | — | 1 | |
| Ventoline® Evohaler® 100 µg/inhalation pMDI alone | — | — | — | — | — | 1 | |
| Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Able spacer | — | — | — | — | — | 1 | |
| Ventoline® Evohaler® 100 µg/inhalation pMDI connectec to Tips-Haler spacer | — | — | — | — | — | 1 | |
| Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Aerochamber plus flow vu valved holding chamber | — | — | — | — | — | 1 | |
| Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Atomizer chamber spacer | — | — | — | — | — | 1 | |
| Ventoline® Evohaler® 100 µg/inhalation pMDI connected to plastic juice cup spacer | — | — | — | — | — | 1 | |
| Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the DispozABLE spacer | — | — | — | — | — | 1 | |
| Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the Lite-Aire collapsible valved holding chamber spacer | — | — | — | — | — | 1 | |
| Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the MDI package | — | — | — | — | — | 1 | |
| Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the hand-made paper sheet spacer | — | — | — | — | — | 1 | |
| L-Citrulline Placebo | — | — | — | — | — | 1 | |
| L Carnitine | — | — | — | — | — | 1 | |
| Standard medical treatment | — | — | — | — | — | 1 | |
| Colistimethate Sodium | — | — | — | — | — | 1 | |
| Tigecycline | — | — | — | — | — | 1 | |
| Tamsulosin 0.4 mg | — | — | — | — | — | 1 | |
| Tamsulosin 0.8 mg | — | — | — | — | — | 1 | |
| Colistimethate sodium for injection, meropenem | — | — | — | — | — | 1 | |
| Amikacin Injection and meropenem | — | — | — | — | — | 1 | |
| diosmin/hesperdin | — | — | — | — | — | 1 | |
| Dapagliflozin | — | — | — | — | — | 2 | |
| Myo-inositol | — | — | — | — | — | 2 | |
| Alpha Lipoic Acid | — | — | — | — | — | 1 | |
| Metfomin | — | — | — | — | — | 1 | |
| pentoxifylline 400 mg | — | — | — | — | — | 1 | |
| Inhaled nitroglycerin | — | — | — | — | — | 1 | |
| Probiotic Formula | — | — | — | — | — | 1 | |
| Control | — | — | — | — | — | 1 | |
| Somatropin (4IU for 1 month) plus, folic acid 400 mcg per day. | — | — | — | — | — | 1 | |
| DHEA plus folic acid 400mcg per day | — | — | — | — | — | 1 | |
| Melatonin | — | — | — | — | 2 |
22 more active programs hidden
Next readouts
- 2025-02-10
- 2025-04-26
- 2025-05-30
- 2025-10-01
- 2025-12-30
- 2026-01-28
- 2026-02-15
- 2026-04-01
- 2026-04-30
- 2026-04-30
Top conditions
- IVF8
- Benign Prostatic Hyperplasia6
- Ureteral Calculi5
- Breast Cancer5
- Pain5
- Lower Urinary Tract Symptoms4
- Chronic Hepatitis C Virus Infection4
- Pediatric Urolithiasis4
Frequently asked questions about Beni-Suef University
- How many clinical trials does Beni-Suef University have on ClinicalTrials.gov?
- Beni-Suef University is listed as the lead sponsor on 321 clinical trials in ClinicalTrials.gov, 88 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Beni-Suef University's trials are in Phase 3?
- 40 of Beni-Suef University's trials are in Phase 3, spread across 62 active drug programs.
- What therapeutic areas does Beni-Suef University focus on?
- Beni-Suef University's most-studied conditions on ClinicalTrials.gov are IVF, Benign Prostatic Hyperplasia, Ureteral Calculi, Breast Cancer, Pain.
- When are Beni-Suef University's next clinical trial readouts?
- Beni-Suef University has 10 upcoming primary-completion readouts tracked here; the soonest is “Assessment of Emergency Spacers Versus Traditional Spacers for Delivery of Aerosolized Drugs”, expected around 2025-02-10.